It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

What a year! What do you think was the most important news in the United States in 2024? This list probably doesn’t reflect that. Rather, it shows what you, the readers, were looking at on ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The hitmaker, 50, was a guest on the show to promote his biopic Better Man, and during the interview, discussed the appearance of Jonno Davies, who plays his younger self.

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...